HSPG2 and colorectal cancer: Specific inactivation of tyrosine kinase receptors, mediated by phospholipase C (PLC), as well as a signal transducer and activator of transcription 3 (STAT3), leads to a decrease in claudin-3 levels in colorectal cancer.